title: The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
authors.affiliation: Department of Medicine, Haematology Section, University Hospital of Verona, Verona, Italy.
authors.forename: Dino
authors.initials: D
authors.lastname: Veneri
authors.affiliation: Department of Medicine, Haematology Section, University Hospital of Verona, Verona, Italy.
authors.forename: Lorenza
authors.initials: L
authors.lastname: Soligo
authors.affiliation: Department of Medicine, Haematology Section, University Hospital of Verona, Verona, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.affiliation: Department of Medicine, Haematology Section, University Hospital of Verona, Verona, Italy.
authors.forename: Achille
authors.initials: A
authors.lastname: Ambrosetti
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D056747:Immunomodulation; D008297:Male; D010976:Platelet Count; D017713:Platelet Transfusion; D011239:Prednisolone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D000069283:Rituximab / Q000008:administration & dosage / Q000627:therapeutic use*; D013926:Thrombopoietin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; C082218:MPL protein, human; D000069283:Rituximab; D013926:Thrombopoietin; D011239:Prednisolone; C488777:romiplostim